Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide LAR pilot study in Indigenous Australians with type 2 diabetes
ACTRN12615000913572Phase 4Completed
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- Jun 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Baker Heart and Diabetes Institute. Primary endpoint: Change in HbA1c at week 20. Started Jun 2016; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12615000913572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000913572.